PharmaSource Podcast

At CDMO Live 2025, a panel sponsored by Aizon explored how pharma companies are transforming external manufacturing operations through digital integration, with experts from sharing practical approac…

“Know your supply chain. Make sure you have it well mapped. The biggest thing that we’ve seen coming out of COVID was investments in technology – that’s what’s helping manufacturers respond to the un…

"There are not that many European CDMOs with commercial expertise in cell therapy - who understand the regulatory requirements and production challenges when you have to manufacture large quantities …

“My ambition for being a CDMO is that there will always be technical challenges, but I want to be transparent about the challenge and provide options to a customer.”

Hanns-Christian Mahler, CEO of ten…

Leaders from the Pharmaceutical Supply Chain Initiative (PSCI) and Manufacture 2030 outlined the mounting pressure on contract manufacturers to address sustainability at CDMO Live 2025, with major ph…

“Nobody knows exactly what will happen, so making yourself anxious about unknowns doesn’t help. You must be prepared for multiple scenarios, ready and flexible to react quickly when changes do occur.…

CDMO Live 2025 Highlights: How Bayer, Boehringer Ingelheim, and Leo Pharma are rebuilding manufacturing strategies

• Complexity Challenge: With thousands of SKUs to manage (Bayer handles 5,000+, half ou…

Gil Roth, president of the Pharma and Biopharma Outsourcing Association (PBOA), delivered a stark assessment of the uncertain regulatory and trade environment facing US drug manufacturers under Donal…

“Over 90% of people you meet in life sciences are going to be dealing with failure every day. You have to normalize failure in this industry to get the success you want,” says Beth Benatti Kennedy, d…

“The pharmaceutical industry is very good at being reactive. If something happens, they have very clear processes, but they’re not so good anticipating change.”

David Schneider, Founder & CEO of Quali…

“In Big Pharma, innovation is often stifled because the bureaucracy and mindset completely kills creativity and intuition needed for discovery. That’s why they now prefer to allocate their early-phas…

“We are privately owned by a Trust, which means all our profits are reinvested in the company. This translates to steady growth – maybe slower compared to other service providers, but we’re quite pro…

“AI doesn’t have to be the first port of call. Many organisations still need to focus on the paper-to-glass journey before they can think about more advanced technologies” 

Vishnu Dwadasi, Director of…

“Our goal is to be more than a service provider. We aim to be a strategic partner that grows with our clients from bench to bedside.” – Dr. Jim Li

Dr. Jim Li, President of CMC Solutions at BioDuro, br…

“Managing hundreds of products across multiple species requires a different approach to network strategy than human pharma,” explains Bernhard Boehm, Head of External Manufacturing for Animal Health …

Exclusive interview for PharmaSource ahead of CDMO Live

“We’ve combined these two solid legacies into a new, agile CDMO with a unique focus on high-value small and medium-scale production,” says Bruce…

“Trust is what your customers need most. They take a great risk when they sign up with you to make their product. They need access within your organization to feel confident you’ll get things done th…

“What we’re witnessing is the rapid dismantling of the US research infrastructure… It’s also an opportunity for us here in Europe to step up” Dr. Oliver Schacht, Managing Director of Life Science Nor…

In the latest episode, we speak to  Payal Gandhi, Management Executive – Business Growth at Blue Jet Healthcare explains how the company transformation from a family-owned business to a publicly list…

“Europe has roughly double the population of the United States but lower pricing, so it’s a balancing act between how much volume can you get and how little price discount you give.” – Joshi Venugopa…